Arshi Shahzad, Author at Exagen Inc.

Exagen Inc. Reports Fourth Quarter and Full Year 2019 Results

SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today reported financial results for the fourth quarter and full year ended December 31, 2019. Recent Highlights: Generated total revenue of $40.4 million for the year …

Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D., as Chief Scientific Officer

SAN DIEGO, March 24, 2020 — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (CMO), and Anja Kammesheidt, Ph.D., as Chief Scientific Officer (CSO). The addition of Drs. Zack and Kammesheidt to the Exagen team will …

Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE® Testing for Patients Suspected of Autoimmune Disease

SAN DIEGO, CA, – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has entered into a strategic partnership with Sonora Quest, the nation’s largest integrated laboratory system. The agreement provides preferred access through Sonora …

Exagen to Announce Fourth Quarter and Year-End 2019 Financial Results on March 25, 2020

SAN DIEGO, March 11, 2020 — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it will release financial results for the fourth quarter and year-end 2019 after the market closes on Wednesday, March 25, 2020. …

Exagen Inc. Partners with Three California Medical Groups to Offer AVISE® Testing as Covered In-Network Benefit for Their Patients

SAN DIEGO, CA – Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced three large medical groups across California have contracted with Exagen Inc. to offer AVISE testing as a covered benefit for patients suspected of having …

Exagen to Present at Cowen and Company 40th Annual Healthcare Conference

SAN DIEGO, CA, February 18, 2020 (GLOBE NEWSWIRE)- Exagen Inc.(Nasdaq: XGN),an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca,CEO of Exagen, will present at the Cowen and Company 40th Annual Healthcare Conference on Monday, March 2, 2020 in …

Exagen, Maker of AVISE Testing, Announces First Blood Test for Anti-CarP, a Breakthrough Bio-marker for Rheumatoid Arthritis

Novel Test Now Available to Aid in Detection and Management of Widespread Debilitating Condition San Diego, CA and Albuquerque, NM, Sep 11, 2018 (GLOBE NEWSWIRE) – Exagen Diagnostics, the leader in specialty rheumatology testing, announced today availability of the first validated blood test to detect autoantibodies against carbamylated proteins (anti-CarP). Studies show that this novel test can add valuable information …

New Study Reveals Valuable New Markers in the Management of Systemic Lupus Erythematosus

Contact: Brian McEvilly – bmcevilly@exagen.com SAN DIEGO, CA and Albuquerque, NM – New evidence supports the role of Exagen’s proprietary blood test in monitoring patients with Systemic Lupus Erythematosus (SLE). Three world-renown lupus centers collaborated to reveal significant association between clinical disease activity and levels of the patented biomarker Erythrocyte-bound C4d (EC4d). SLE is known as the great masquerader and, …

Exagen Points the Way for Patients with Difficult-to-Diagnose Disease

Contact: Vince Heald, Beck Ellman Heald (vheald@behmedia.com) – 858-453-9600 SAN DIEGO, CA and Albuquerque, NM – May is “Lupus Awareness Month” and according to the Lupus Foundation of America, polls show that some two thirds of Americans are unfamiliar with the complex disease that affects approximately 5 million people around the world. “There is a need for greater awareness among …

Exagen announces collaboration with GSK to drive greater awareness about challenges facing lupus diagnostics and management

Current average time for lupus diagnosis of nearly six years must be improved upon Issued ALBUQUERQUE, NM and SAN DIEGO, CA- Exagen Diagnostics, Inc. today announced a first-of-its kind collaboration with GSK to raise awareness of its laboratory tests, which facilitate early diagnosis and management of systemic lupus erythematosus (SLE), the most common form of lupus, a complex, incurable autoimmune …

Page 1 of 3
1
2
3
→